Original article

Association of syntax score with short-term outcomes among acute ST-elevation myocardial infarction patients undergoing primary PCI

Sarita Choudhary
Cardiology Department, S.M.S Hospital, Jaipur, India

ARTICLE INFO

Article history:
Received 20 March 2016
Accepted 8 August 2016
Available online 24 August 2016

Keywords:
SYNTAX score
PCI
Myocardial infarction
STEMI
Mortality

ABSTRACT

Objective: Syntax score (SX) has emerged as a reproducible angiographic tool to quantify the extent of coronary artery disease based on location and complexity of each lesion. It has been shown to predict long-term clinical outcomes in patients with left main or multi-vessel disease and recently also in ST-segment elevation myocardial infarction undergoing primary PCI. The aim of this study was to evaluate whether the syntax score is associated with short-term cardiovascular outcomes in patients treated with primary percutaneous coronary intervention (PCI) for acute ST-segment elevation myocardial infarction (STEMI).

Methods: Syntax score was determined in 90 consecutive patients (mean age 54.2 ± 11.6) of STEMI undergoing primary PCI. Outcomes were stratified according to syntax score groups: SX low (n = 33), SX mid 16–22 (n = 30), and SX high ≥23 (n = 27). The primary endpoint was all-cause mortality at 30 days. Secondary endpoints were nonfatal major adverse cardiac and cerebrovascular events (MACE) defined as a composite of any repeat revascularization, acute coronary syndrome, and stroke at 30 days in patients discharged alive.

Results: Mortality at 30 days was higher in the SX high group compared to the SX mid and SX low group (18.5% vs 3.3%, p = 0.011), MACE at 30 days was higher in SX high group compared to SX mid and SX low group (48.1% vs 16.6% vs 9.1%, p = 0.001).

Conclusions: The syntax score is associated with 30-day mortality in patients with STEMI undergoing primary PCI. In those discharged, it is associated with risk of MACE at 30 days.

© 2016 Cardiological Society of India. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

1. Introduction

Acute treatment of ST elevation myocardial infarction (STEMI) is restoration of myocardial perfusion by recanalization of the occluded vessel. Early reperfusion is associated with better outcomes. Thus primary percutaneous coronary intervention (PCI) has become the treatment of choice for acute STEMI. Most scoring systems such as TIMI, GRACE that predict adverse events in patients with acute coronary syndrome (ACS) rely on clinical variables such as age, heart rate, blood pressure, Killip class, ST-segment changes, and serum creatinine levels, while not taking into account the characteristics of coronary lesions.1–4

The SYNTAX (Synergy between Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery) score (SX) has been developed as a comprehensive angiographic scoring tool for quantification of coronary lesions with respect to their number, location, and complexity. It was initially tested in patients with stable coronary artery disease, multi-vessel disease or complex coronary lesions allocated to PCI or coronary artery bypass graft (CABG) surgery in the landmark SYNTAX trial.5–8 Subsequently, this score was also validated for left main disease and in all-comers population undergoing PCI9,10 It is a good predictor of adverse cardiovascular events including cardiac death, myocardial infarction (MI), and target lesion revascularisation.9,11,12 Recently, it has also validated for risk stratification in STEMI undergoing primary PCI, where it was found associated with mortality, major adverse cardiac events, and stent thrombosis at 1-year follow-up.13 Previous studies using the syntax score have focused on long-term clinical outcomes after PCI and data on its impact on short-term outcome is limited. Thus, we determined the association of syntax scores with short-term outcomes in patients with STEMI undergoing primary PCI.

2. Methods

2.1. Study population

All patients who were admitted at our institution with STEMI and underwent primary PCI during January 2014 to January
2015 were included in the present analysis ($n = 90$; mean age $54.2 \pm 11.6$ years). None of these patients had been treated with fibrinolytic therapy. Performa has been designed to collect information regarding age, gender, history of risk factors, diabetes, dyslipidemia, hypertension, smoking, and family history of premature coronary artery disease (CAD). Patient’s clinical parameters, left ventricular function, and Killip class were recorded. Laboratory data including hemoglobin, total leukocyte count, platelet count, creatinine, and cardiac enzymes, etc. were noted. Clinical characteristics at baseline are shown in Table 1. Pre-treatment with drugs according to standard guidelines was initiated. Urgent diagnostic coronary angiography followed by primary PCI was performed. All primary PCI procedures were performed by experienced interventional cardiologists using femoral approach. The decision to perform PCI and to implant bare-metal or drug-eluting stents was at the discretion of the operator. Current guidelines for the management of STEMI indicate that culprit-only intervention should be performed acutely during primary PCI in the absence of cardiogenic shock and thus, it was followed at our institution. Pre-dilatation or post-dilatation after stent implantation, thrombosis, use of eptifibatide was at the operator’s choice. There was no restriction on the type, length or number of implanted stents. Baseline lesion and procedure characteristics are listed in Table 2. Exclusion criteria were previous CABG surgery or PCI and if emergent CABG surgery indication was present.

### 2.2. Determination of Syntax score

The Syntax score was calculated from baseline angiograms, for all coronary lesions with a diameter stenosis greater than 50% in vessels larger than 1.5 mm, using syntax score online calculator. All angiographic variables involved in the calculation were computed by two independent investigators who were blinded to all clinical data. If the infarct-related artery was occluded, it was scored as an occluded artery of $<3$-month duration.

#### 2.3. Study endpoints

The study’s primary endpoint was mortality at 30-day follow-up. Secondary endpoints were nonfatal major adverse cardiac and cerebrovascular events (MACE) defined as a composite of any repeat revascularization, acute coronary syndrome and stroke within 30-day follow-up period in discharged patients. Any repeat revascularization was defined as repeat PCI or bypass grafting of both infarct related artery and non-infarct related artery, driven by ischemic symptoms.

#### 2.4. Statistical methods

Continuous variables are expressed as mean and standard deviation. Categorical variables are expressed as percentage. The difference in means would be analyzed using student’s ‘t’ test. A two-sided $p < 0.05$ was considered as statistically significant. The difference is categorical variables were analyzed using Chi-square test.

### 3. Results

Out of 90 patients undergoing primary PCI for STEMI during 2014–2015, mean syntax score was 17.4 (range 6–46). Groups were computed as SX low $\leq 15$ ($n = 33$), SX mid 16–22 ($n = 30$), and SX high $\geq 23$ ($n = 27$). Mean age of patients undergoing PCI during primary PCI for STEMI was 54.2 (range 43–65 years). None of these patients had been treated with fibrinolytic therapy. Performa has been designed to collect information regarding age, gender, history of risk factors, diabetes, dyslipidemia, hypertension, smoking, and family history of premature coronary artery disease (CAD). Patient’s clinical parameters, left ventricular function, and Killip class were recorded. Laboratory data including hemoglobin, total leukocyte count, platelet count, creatinine, and cardiac enzymes, etc. were noted. Clinical characteristics at baseline are shown in Table 1. Pre-treatment with drugs according to standard guidelines was initiated. Urgent diagnostic coronary angiography followed by primary PCI was performed. All primary PCI procedures were performed by experienced interventional cardiologists using femoral approach. The decision to perform PCI and to implant bare-metal or drug-eluting stents was at the discretion of the operator. Current guidelines for the management of STEMI indicate that culprit-only intervention should be performed acutely during primary PCI in the absence of cardiogenic shock and thus, it was followed at our institution. Pre-dilatation or post-dilatation after stent implantation, thrombosis, use of eptifibatide was at the operator’s choice. There was no restriction on the type, length or number of implanted stents. Baseline lesion and procedure characteristics are listed in Table 2. Exclusion criteria were previous CABG surgery or PCI and if emergent CABG surgery indication was present.

### Table 1: Baseline characteristics of patients according to syntax score (SXS).

| Variables                  | N = 90 (%) | SX low n = 33 (37%) | SX mid n = 30 (33%) | SX high n = 27 (30%) | p value |
|----------------------------|------------|---------------------|---------------------|----------------------|---------|
| Age, year                  | 54.2       | 51.3 (±12.74)       | 55.9 (±11.04)       | 55.7 (±10.73)        | 0.213   |
| Gender                     |            |                     |                     |                      |         |
| Male                       | 70 (77.8%) | 28 (84.8%)          | 22 (73.3%)          | 20 (74.1%)           | 0.47    |
| Female                     | 20 (22.2%) | 5 (15.2%)           | 8 (26.7%)           | 7 (25.9%)            |         |
| Risk factors               |            |                     |                     |                      |         |
| Tobacco use                | 49 (54.4%) | 17 (51.5%)          | 17 (56.7%)          | 15 (55.5%)           | 0.911   |
| Hypertension               | 39 (43.3%) | 15 (45.4%)          | 12 (40%)            | 12 (44.4%)           | 0.9     |
| Diabetes                   | 24 (26.7%) | 6 (18.2%)           | 8 (26.7%)           | 10 (37%)             | 0.259   |
| Hyperlipidemia             | 20 (22.2%) | 7 (21.1%)           | 7 (23.3%)           | 6 (22.2%)            | 0.98    |
| F/H CAD                    | 14 (15.5%) | 5 (15.1%)           | 5 (16.7%)           | 4 (14.8%)            | 0.978   |
| Clinical profile           |            |                     |                     |                      |         |
| SBP, mm Hg                 | 120.6      | 126.3 (±17.40)      | 124.8 (±13.89)      | 110.6 (±13.47)       | 0       |
| Heart rate                 | 75.4       | 72.4 (±11.3)        | 73.1 (±11.62)       | 80.8 (±14.7)         | 0.023   |
| Killip class ≥2            | 13 (14.4%) | 2 (6.1%)            | 5 (16.6%)           | 6 (22.2%)            | 0.19    |
| Creatinine (mg/dL)         | 1.1        | 1.0 (±0.24)         | 1.1 (±0.36)         | 1.2 (±0.49)          | 0.118   |
| Ejection fraction (%)      | 42.3       | 45.5 (±6.90)        | 41.8 (±6.96)        | 39.07 (±7.08)        | 0.002   |
| Time symptom onset to hospital [min] | 211 | 218 | 195 | 221 |
| Door to balloon time [min] | 82         | 74                  | 89                  | 82                   |         |
| Total ischemic time (TIT)  | 293        | 292 (±144.6)        | 284 (±144)          | 303 (±155.4)         | 0.887   |
| Type of STEM               |            |                     |                     |                      |         |
| AWMI                       | 49 (54.4%) | 15 (45.4%)          | 15 (50%)            | 19 (70.4%)           | 0.263   |
| IWMI ± RV/PWMI             | 32 (35.6%) | 13 (39.4%)          | 13 (43.3%)          | 6 (22.2%)            |         |
| Others                     | 9 (10%)    | 5 (15.2%)           | 2 (6.7%)            | 2 (7.4%)             |         |
| In-hospital medication     |            |                     |                     |                      |         |
| Aspirin                    | 90 (100%)  | 33 (100%)           | 30 (100%)           | 27 (100%)            | 1       |
| Clopidogrel/prasugrel       | 90 (100%)  | 33 (100%)           | 30 (100%)           | 27 (100%)            | 1       |
| Beta blockers              | 70 (77.8%) | 25 (75.7%)          | 25 (83.3%)          | 20 (74.1%)           | 0.661   |
| ACE inhibitors/ARB         | 80 (88.9%) | 31 (93.9%)          | 27 (90%)            | 22 (81.5%)           | 0.303   |
| Statins                    | 90 (100%)  | 33 (100%)           | 30 (100%)           | 27 (100%)            | 1       |
| Inotropic drugs            | 10 (11.1%) | 1 (3.0%)            | 3 (10%)             | 6 (22.2%)            | 0.061   |
| Diuretics                  | 9 (10%)    | 2 (6.1%)            | 3 (10%)             | 4 (14.8%)            | 0.531   |
| GPIIb/IIIa inhibitors      | 43 (47.8%) | 15 (45.5%)          | 14 (46.7%)          | 14 (51.8%)           | 0.876   |
SX high $\geq 23$ ($n = 27$). Baseline clinical and angiographic characteristics of patients are presented in Table 1. Mean age, gender, baseline investigations, and risk factor profile – hypertension, dyslipidemia, smoking, diabetes, and family history of CAD were similar between the three groups. At presentation, patients in SX high group had higher heart rate (80.8 vs 73.1 vs 72.4, $p < 0.001$) and number of vessels involved (2.0 vs 1.3 vs 1.1, $p = 0.014$) and number of stents implanted (1.6 vs 1.3 vs 1.1, $p < 0.001$) were higher in SX high group than SX mid and low groups. Left ventricular ejection fraction (mean) was lower in patients with high syntax score compared to those with mid-low scores (39.07% vs 41.8% vs 45.5%, $p = 0.002$). Killip class, total ischemic time, type of STEMI, and in hospital treatment did not differ between the groups.

There were higher rates of left anterior descending as the culprit vessel in SX high group (70.4% vs 43.3% vs 24.25, $p = 0.012$). Triple vessel disease (37.1% vs 20% vs 6.1%, $p = 0.014$) and number of vessels involved (1.6 vs 1.3 vs 1.1, $p < 0.001$) were higher in SX high group than SX mid and low groups. As shown in our study, patients with high syntax score had higher prevalence of triple vessel disease compared with those in the SX mid and low. The well-established association between multi-vessel disease and cardiogenic shock may partly explain the increase in the peri-procedural risk and high mortality. In our study patients with high syntax score had greater systolic dysfunction (lower LVEF) and greater LAD occlusion, so they had greater area of myocardium involvement, which may partly explain bad outcome in this group. Previous studies have shown syntax score as a predictor for TIMI flow grade $\leq 3$ and no reflow, which are associated with bad outcome. Biondi-Zoccai et al. showed in a meta-analysis that patients of STEMI with multi-vessel disease have worse clinical outcomes than those with single-vessel disease. In addition, as shown in our study, patients with high syntax score had greater systolic dysfunction (lower LVEF) and greater LAD occlusion, so they had greater area of myocardium involvement, which may partly explain bad outcome in this group. Previous studies have shown syntax score as a predictor for TIMI flow grade $\leq 3$ and no reflow, which are associated with bad outcome. Biondi-Zoccai et al. showed in a meta-analysis that patients of STEMI with multi-vessel disease have worse clinical outcomes than those with single-vessel disease. Likewise, Brown et al. showed that lesion complexity was predictive of mortality at a follow-up of 2 years. This observation presumably reflects the predominant role of anatomic complexity of coronary lesions in determining mortality.

MACE were more common in patients with SX high group compared to SX mid and SX low group (48.1% vs 16.6% vs 9.1%, $p = 0.001$). In our study patients with high syntax score had higher rates of any repeat revascularization than those with intermediate

### Table 2

| Variables | SX low $n = 33$ (%) | SX mid $n = 30$ (%) | SX high $n = 27$ (%) |
|-----------|-------------------|-------------------|---------------------|
| SX score  | 17.4 (9.9)        | 18.4 (13.2)       | 23.9 (12.6)         |
| IRA       |                   |                   |                     |
| Left anterior descending | 40 (44.4%) | 20 (60.6%) | 13 (43.3%) |
| Circumflex artery | 15 (46.7%) | 11 (33.3%) | 11 (36.7%) |
| Right coronary artery | 35 (38.9%) | 7 (21.2%) | 3 (10%) |
| Left main disease | 1 (1.1%) | 1 (3.3%) | 0 |
| Number of diseased vessels |                   |                   |                     |
| SVD       | 42 (46.7%)        | 20 (60.6%)       | 13 (43.3%)         |
| DVD       | 30 (33.3%)        | 11 (33.3%)       | 11 (36.7%)         |
| TVD       | 18 (20%)          | 2 (6.1%)         | 6 (20%)            |
| Total occlusion with thrombus | 81 (90%) | 29 (87.9%) | 27 (90%) |
| Total no. of stents implanted | 1.3 | 1.1 ($\pm 0.28$) | 1.3 ($\pm 0.45$) |
| Stent type |                   |                   |                     |
| BMS       | 19 (21.1%)        | 7 (21.2%)        | 7 (23.3%)          |
| DES       | 71 (78.9%)        | 26 (78.8%)       | 23 (76.7%)         |

### Table 3

| Variables | N=90 (%) | SX low $n = 33$ (%) | SX mid $n = 30$ (%) | SX high $n = 27$ (%) |
|-----------|----------|-------------------|-------------------|---------------------|
| All cause mortality | 6 (6.7%) | 0 | 1 (3.3%) | 5 (18.5%) |
| Cardiac death | 5 (5.5%) | 0 | 0 | 5 (18.5%) |
| Any repeat revascularization | 8 (8.9%) | 1 (3%) | 1 (3.3%) | 6 (22.2%) |
| Acute coronary syndrome | 10 (11.1%) | 1 (3%) | 3 (10%) | 6 (22.2%) |
| Cerebrovascular events | 3 (3.3%) | 1 (3%) | 1 (3.3%) | 1 (3.7%) |
| Rehospitalization | 15 (16.7%) | 2 (6.1%) | 5 (16.7%) | 8 (29.6%) |
| Overall MACE | 21 (23.3%) | 3 (9.1%) | 5 (16.6%) | 13 (48.1%) |
and low score (22.2% vs 3.3% vs 3%, p = 0.014). Since patients in SX high group had more multi-vessel disease or complex lesions, not opening the non-culprit lesions during the initial procedure may partly explain these findings. But our study followed PCI of infarct related artery in the light of current ACC/AHA STEMI guidelines. Recently, the Preventive Angioplasty in Acute Myocardial Infarction study reported that the primary outcome of cardiac death, MI, or refractory angina was significantly less common in the preventive-PCI group, as compared with optimal medical therapy alone. Therefore, the best strategy for staged revascularization in STEMI with MVD is yet to be clarified further. Similarly, Sorajja et al. reported that multi-vessel disease was associated with a higher rate of revascularization in patients with STEMI after primary PCI. Thus, a high syntax score was found to be associated with re-infarction and need for revascularization.

Occurrence of cerebrovascular events did not differ between the three groups.

The present study shows that the high Syntax score is associated with mortality and MACE at 30 days in patients with STEMI undergoing primary PCI. These results are in agreement with recent studies showing that the syntax score has risk predictive value both in patients undergoing elective PCI and in those undergoing primary PCI for STEMI.

4.1. Study limitations

Number of patients in our study group was less, but it was sufficient to reach statistically significant results and conclusions particularly with respect to 30-day mortality.

Conflicts of interest

The author has none to declare.

References

1. Addala S, Grines CL, Dixon SR, et al. Predicting mortality in patients with ST-elevation myocardial infarction treated with primary percutaneous coronary intervention (PAMI risk score). Am J Cardiol. 2004;93(5):629–632.
2. Halkin A, Singh M, Nikolsky E, et al. Prediction of mortality after primary percutaneous coronary intervention for acute myocardial infarction: the CADILLAC risk score. J Am Coll Cardiol. 2005;45(9):1397–1405.
3. Eagle KA, Lim MJ, Dabbous OH, et al. A validated prediction model for all forms of acute coronary syndrome: estimating the risk of 6-month postdischarge death in an international registry. JAMA. 2004;291(22):2727–2733.
4. Morrow DA, Antman EM, Charlesworth A, et al. TIMI risk score for ST-elevation myocardial infarction: a convenient, bedside, clinical score for risk assessment at presentation: an intravenous nPA for treatment of infarcting myocardium early II trial substudy. Circulation. 2000;102(17):2031–2037.
5. Serruys PW, Morice MC, Kappetein AP, et al. Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease. N Engl J Med. 2009;360:961–972.
6. Siagno G, Morel MA, Kappetein AP, et al. The SYNTAX score: an angiographic tool grading the complexity of coronary artery disease. EuroIntervention. 2005;1:219–227.
7. Serruys PW, Onuma Y, Garg S, et al. Assessment of the SYNTAX score in the Syntax study. EuroIntervention. 2009;5:50–56.
8. Valgimigli M, Serruys PW, Tsuchida K, et al. Cyphering the complexity of coronary artery disease using the syntax score to predict clinical outcome in patients with three-vessel lumen obstruction undergoing percutaneous coronary intervention. Am J Cardiol. 2007;99(8):1072–1081.
9. Capodanno D, Capranzano P, Di Salvo ME, et al. Usefulness of SYNTAX score to select patients with left main coronary artery disease to be treated with coronary bypass graft. JACC Cardiovasc Interv. 2009;2(8):731–738.
10. Capodanno D, Di Salvo ME, Cincotta G, et al. Usefulness of the SYNTAX score for predicting clinical outcome after percutaneous coronary intervention of unprotected left main coronary artery disease. Circ Cardiovasc Interv. 2009;2(4):302–308.
11. Magro M, Nauta S, Simsek C, et al. Value of the SYNTAX score in patients treated by primary percutaneous coronary intervention for acute ST-elevation myocardial infarction: the MI SYNTAX score study. Am Heart J. 2011;161(4):771–781.
12. Biondi-Zoccai G, Lotrone I, Ichihara K, et al. Management of multivessel coronary disease after ST-elevation myocardial infarction treated by primary coronary angioplasty. Am Heart J. 2010;160(Suppl. 6):S26–S35.
13. Brown AJ, McCormick LM, Gajendragadkar PR, Hoole SP, West NE. Initial SYNTAX score predicts major adverse cardiac events after percutaneous coronary revascularization. Angiology. 2013. (published online 29.04.13).
14. Jeger RV, Radovanovic D, Hunziker PR, et al. Ten-year trends in the incidence and treatment of cardiogenic shock. Ann Intern Med. 2008;149(9):618–626.
15. Garg S, Sarno G, Serruys PW, et al. STRATEGY and MULTISTRATEGY Investigators. Prediction of 1-year clinical outcomes using the SYNTAX score in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: a substudy of the STRATEGY (single high-dose bolus tirofiban and sirolimus-eluting stent versus abciximab and bare-metal stent in acute myocardial infarction) and MULTISTRATEGY (multicenter evaluation of single high-dose bolus tirofiban versus abciximab with sirolimus-eluting stent or bare-metal stent in acute myocardial infarction) trial studies. JACC Cardiovasc Interv. 2011;4(1):66–75.
16. Sorajja P, Gersh BJ, Cox DA, et al. Impact of multivessel disease on reperfusion success and clinical outcomes in patients undergoing primary percutaneous coronary intervention for acute myocardial infarction. Eur Heart J. 2007;28:1709–1716.
17. Patrick T, O’Gara, Frederick G, et al. 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2013;127:
18. Wald DS, Morris JK, Wald NJ, et al. Randomized trial of preventive angioplasty in myocardial infarction. N Engl J Med. 2013;369:1115–1123.
19. Morishima I, Sone T, Okumura K, et al. Angiographic no-reflow phenomenon as a predictor of adverse long-term outcome in patients treated with percutaneous transluminal coronary angioplasty for first acute myocardial infarction. J Am Coll Cardiol. 2000;36:1202–1209.
20. Magro M, Nauta ST, Simsek C, et al. Usefulness of the SYNTAX score to predict “no reflow” in patients treated with primary percutaneous coronary intervention for ST-segment elevation myocardial infarction. Am J Cardiol. 2012;109:601–606.